Biodistribution of extracellular vesicles following administration into animals: A systematic review.
Kang M, Jordan V, Blenkiron C, Chamley LW. · 2021
Read Biodistribution of extracellular vesicles following administration into animals: A systematic review. by Kang M, Jordan V, Blenkiron C, Chamley LW. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8224174.txt.
Introduction
Kang and co-authors review where extracellular vesicles travel after dosing in animals. Vesicles carry signals between cells and may serve as drug carriers. Knowing where they end up bridges lab work and body effects.
The systematic review pooled studies that dosed animals with vesicles. Small vesicles gathered most in the liver. Their signal peaked in liver and kidney within the first hour. Large vesicles favoured the lungs early, then shifted toward the liver. Timing changed the map for both sizes. Such maps help design vesicle therapies that reach the right organ.
Catalog record
| CREATOR | Kang M, Jordan V, Blenkiron C, Chamley LW. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Biodistribution of extracellular vesicles following administration into animals: A systematic review By Matthew Kang, Vanessa Jordan, Cherie Blenkiron, Lawrence W Chamley Published in: Journal of Extracellular Vesicles DOI: 10.1002/jev2.12085 ABSTRACT Abstract In recent years, attention has turned to examining the biodistribution of EVs in recipient animals to bridge between knowledge of EV function in vitro and in vivo. We undertook a systematic review of the literature to summarize the biodistribution of EVs following administration into animals. There were time‐dependent changes in the biodistribution of small‐EVs which were most abundant in the liver. Detection peaked in the liver and kidney in the first hour after administration, while distribution to the lungs and spleen peaked between 2–12 h. Large‐EVs were most abundant in the lungs with localization peaking in the first hour following administration and decreased between 2–12 h. In contrast, large‐EV localization to the liver increased as the levels in the lungs decreased. There was moderate to low localization of large‐EVs to the kidneys while localization to the spleen was typically low. Regardless of the origin or size of the EVs or the recipient species into which the EVs were administered, the biodistribution of the EVs was largely to the liver, lungs, kidneys, and spleen. There was extreme variability in the methodology between studies and we recommend that guidelines should be developed to promote standardization where possible of future EV biodistribution studies. Keywords: apoptotic body, biodistribution, exosome, extracellular vesicles, microparticle, microvesicle, targeting INTRODUCTION Extracellular vesicles (EVs) is a collective term used to describe phospholipid bi‐layered biological packets that are produced and released by all prokaryote and eukaryote cells studied to date. These entities were reported as early as 1946 by Chargaff and West who observed particles derived from platelets from normal plasma (Chargaff & West, 1946). Until recently EVs were thought of as a means of disposing cellular wastes. However, in 1996 Raposo and colleagues showed that B lymphoblastoid cells release EVs carrying MHC class II that could present antigen in vivo inducing antigen‐specific MHC class II‐restricted T cell responses (Raposo et al., 1996). The field of EV research began an exponential increase around 2006 (Witwer & Théry, 2019) when several studies demonstrated that EVs carry biological cargos that can transfer to and alter the behaviour of recipient cells (Ratajczak et al., 2006; Skog et al., 2008; Valadi et al., 2007). Please refer to Figure 1 of https://www.mdpi.com/621550 for a succinct outline of major discoveries in the EV field (Yi et al., 2020). The nomenclature of EVs in the literature is problematic with multiple disciplines creating different names for EVs. For example, platelet‐derived platelet dust, prostate‐derived prostasomes, cancer cell‐derived oncosomes, dendritic cell‐derived dexasomes, cartilage and bone‐derived matrix vesicles, cardiac progenitor cell and myocyte‐derived cardiosome, etc. (Aalberts et al., 2014; Hargett & Bauer, 2013; Le Pecq, 2005; Tanimura et al., 1983). For greater standardization, typically, EVs are often grouped into three terminologies based on the size of the EVs. Roughly speaking, apoptotic bodies are 800–5000 nm in diameter, microvesicles are between 50–1000 nm in diameter, and nanovesicles (including exosomes) are between 40 and 150 nm in diameter (Crescitelli et al., 2013). Exosomes have been extensively studied and are produced initially as intraluminal vesicles (ILV) in multivesicular bodies (MVB) and are then released from the cell. In contrast, microvesicles are believed to be released by outward blebbing of the cell plasma membrane, while apoptotic bodies are released from cells undergoing apoptosis. Apart from these three, the types of EVs can be dissected even further, as evidenced by Zhang et al. (2018) who showed that exosomes can be fractionated into even smaller sub‐populations called ‘large‐exosomes’, ‘small‐exosomes’, and non‐membranous ‘exomeres’. At the other end of the spectrum, EVs far larger than apoptotic bodies have also been well documented, such as macro‐vesicles that are multi‐nucleated EVs released from the unique multinucleated syncytiotrophoblast of the human placenta. Macrovesicles have a diameter ranging between 20 μm to several hundred micrometres (Tong & Chamley, 2015). Given this wide spectrum of different EV types and nomenclature and confusion over the correct identification of EVs, the ‘Minimal Information for studies of extracellular vesicles (MISEV) 2018′ guideline has suggested the use of two broad terms for EVs based on their size. Small‐EVs are < 100 nm, and large‐EVs are typically > 200 nm (Théry et al., 2018). These MISEV‐derived terminologies will be employed in this review. Recently the attention has turned to examining the fate of EVs, i.e. their biodistribution upon administration into recipient animals in vivo. Research effort analysing EV biodistribution is a pivotal stepping‐stone in the maturation of the EV field as it highlights the junction between in vitro knowledge and physiological significance. It is especially important for EVs that are designed for therapeutic purposes as it can determine the level of on‐target, as well as off‐target effects of EVs (Yamashita et al., 2018). For example, mesenchymal stem cell (MSC)‐derived small‐EVs have been shown to target preferentially to kidneys in animals with kidney injuries but not control mice (Grange et al., 2014). Current in vivo studies of EV biodistribution are extremely heterogeneous with widely varying methodologies. Reported studies include wide differences in 1) doses of EVs, 2) routes of administration, 3) recipient animals, 4) organs investigated, 5) timepoints analysed, 6) methods of tracking (such as fluorescent dyes, bioluminescence, radiolabel), and 7) techniques of EV isolation. This diversity creates challenges when trying to compare studies and produce a general understanding of the biodistribution of EVs in vivo. With these challenges in mind, in this review we aim to summarize the biodistribution of natural EVs that are not ‘modified’ to specifically target cell types or organs. This was done by performing a systemic review of the current literature. METHODS Search strategy 2.1. Guided by the PRISMA guidelines, we performed a systemic search of the literature to identify publications that investigated the biodistribution of EVs in vivo. To ensure maximal coverage of the literature, three databases were utilized: Ovid Biosis, Ovid Medline, and Ovid Embase. Search was performed and retrieved on 26th of June 2019 using a broad search category for keywords (‘extracellular vesicle’) AND (‘biodistribution’ OR ‘targeting’) in addition to numerous synonyms for each keyword. The synonyms for extracellular vesicle included (‘microparticle’ OR ‘exosome’ OR ‘microvesicle’ OR ‘nanovesicle’ OR ‘macrovesicle’ OR ‘microparticle’ OR ‘nanoparticle’ OR ‘syncytial nuclear aggregate’ OR ‘shedding vesicle’ OR ‘membrane vesicle’ OR ‘budding vesicle’ OR ‘blebbing vesicle’ OR ‘apoptotic bleb’ OR ‘apoptotic body’ OR ‘extracellular body’ OR ‘exovesicle’). The synonyms for biodistribution included (‘tissue distribution’), while the synonyms for targeting included (‘traffic’ OR ‘docking’ OR ‘recipient’). All records were limited to the English language. The references of the selected records that were eligible for review were screened for additional relevant publications. Eligibility criteria and search result 2.2. A total of 29532 records were retrieved from Biosis (6618), Medline (8785), and Embase (14129) (Figure 1). After removing duplicates, the titles of 17608 records were screened and 14588 records were discarded as the titles did not include keywords, ‘extracellular vesicles’ and ‘biodistribution or targeting’ or its synonyms or that did not present primary data or were conference abstracts. The abstracts of the remaining 3020 studies were screened, and 2681 studies were excluded as they did not relate to EV biodistribution. The